Clinical Trials Logo

Clinical Trial Summary

This is a pilot study to determine if adults and children with neurofibromatosis type 1 who have plexiform tumors given Sutent® respond to this drug therapy.


Clinical Trial Description

This is an open-label pilot study to evaluate the efficacy of Sutent® in individuals with NF1 who have clinically significant plexiform tumors. A secondary goal of this study will be to seek to improve on current and novel tools to evaluate tumor response of plexiform tumors. The rationale for this study arises from the response of human and murine NF1 cells to Sutent® in vitro and the clinical response of individuals with NF1 using a similar drug,Gleevec®. Following enrollment adult subjects will start receiving Sutent® by month at 25mg once a day for 28 days. Subjects will then have 14 days without taking any Sutent®. If tolerated the dose will be increased to 37.5mg and 50mg with the same regimen (28 days of taking medication followed by 14 without). Children will be started on a dose of 10mg/m2/day once a day for 28 days. They will then have 14 days without taking any Sutent®. If tolerated the dose will be increased to 15mg/m2/day. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01402817
Study type Interventional
Source Indiana University
Contact
Status Terminated
Phase Phase 2
Start date March 2012
Completion date February 14, 2018

See also
  Status Clinical Trial Phase
Completed NCT00754780 - Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 Phase 2
Completed NCT00589784 - Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Phase 2
Recruiting NCT04463316 - GROWing Up With Rare GENEtic Syndromes
Completed NCT01673009 - Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Phase 2
Recruiting NCT00598351 - Natural History Study of Patients With Neurofibromatosis Type 2
Completed NCT02298270 - Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype N/A
Completed NCT02101736 - Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults Phase 2
Completed NCT01633008 - Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain Early Phase 1
Terminated NCT04461886 - A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I Phase 3
Completed NCT01275586 - Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Early Phase 1
Completed NCT02435628 - Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With NF N/A
Active, not recruiting NCT01140360 - Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas Phase 1/Phase 2
Completed NCT02211768 - Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Phase 1
Completed NCT00508235 - Quality of Friendships in Children With Neurofibromatosis N/A
Completed NCT01639950 - Validating Pain Scales in Children and Young Adults